Login to Your Account



Other news to note


Thursday, February 20, 2014
Active Biotech AB, of Lund, Sweden, said partner Teva Pharmaceutical Industries Ltd., of Jerusalem, decided not to proceed to the randomization stage of the planned Libretto trial for Laquinimod (nerventra), an oral immunomodulator, in the treatment of relapsing remitting multiple sclerosis (RRMS), as the current design is no longer aligned with the regulatory strategy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription